Pragmatic Approaches to Drug Safety Across the Premarketing and Postmarketing Continuum

This session will address the concepts that encompass stakeholder perceptions in the iterative assessment of benefit-risk. Several models of structured benefit-risk assessment, as well as FDA’s current approach to benefit-risk, will be explained. The session will conclude with an introduction to risk communication.